List of works - Daiki Miki

A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region

scientific journal article

A genome-wide association study of chronic hepatitis B identified novel risk locus in a Japanese population

scientific article published on 12 July 2011

A nonsynonymous polymorphism in semaphorin 3A as a risk factor for human unexplained cardiac arrest with documented ventricular fibrillation

scientific article

A novel TK-NOG based humanized mouse model for the study of HBV and HCV infections.

scientific article published on 16 October 2013

A translational study of resistance emergence using sequential direct-acting antiviral agents for hepatitis C using ultra-deep sequencing.

scientific article published on 30 July 2013

Achievement of sustained viral response after switching treatment from pegylated interferon α-2b to α-2a and ribavirin in patients with recurrence of hepatitis C virus genotype 1 infection after liver transplantation: a case report.

scientific article published on 25 August 2011

Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection

scientific article

Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A.

scientific article published on 4 April 2015

Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy

scientific article published on 17 June 2015

Circulating microRNA-22 correlates with microRNA-122 and represents viral replication and liver injury in patients with chronic hepatitis B.

scientific article published in May 2013

Clinicopathological features of elderly patients with hepatitis C virus-related hepatocellular carcinoma

scientific article published on 23 July 2008

Combination therapies with daclatasvir and asunaprevir on NS3-D168 mutated HCV in human hepatocyte chimeric mice.

scientific article

Common Variant Near HEY2 Has a Protective Effect on Ventricular Fibrillation Occurrence in Brugada Syndrome by Regulating the Repolarization Current

scientific article published on January 2016

Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy.

scientific article published in June 2011

Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients.

scientific article published on 31 May 2010

Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus

scientific article published on 3 April 2017

Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study.

scientific article

Differences in serum microRNA profiles in hepatitis B and C virus infection.

scientific article published on 5 November 2014

Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones

scientific article published on 26 October 2015

Effects of bisphosphonate zoledronic acid in hepatocellular carcinoma, depending on mevalonate pathway.

scientific article published on March 2015

Effects of structural variations of APOBEC3A and APOBEC3B genes in chronic hepatitis B virus infection

scientific article published on 25 September 2009

Efficacy and safety of daclatasvir plus asunaprevir therapy for chronic hepatitis C patients with renal dysfunction.

scientific article

Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients.

scientific article published on 28 June 2017

Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1.

scientific article published on 19 June 2014

Eradication of hepatitis C virus genotype 1 after liver transplantation by interferon therapy before surgery: Report of three patients with analysis of interleukin-28 polymorphism, hepatitis C virus core region and interferon-sensitivity determining

scientific article published in November 2011

Erratum to: Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy

scientific article published in January 2018

Establishment of an infectious genotype 1b hepatitis C virus clone in human hepatocyte chimeric mice

scientific article

G to A hypermutation of TT virus.

scientific article published on 6 February 2010

G-to-A hypermutation in hepatitis B virus (HBV) and clinical course of patients with chronic HBV infection

scientific article

Genetic analyses reveal a role for vitamin D insufficiency in HCV-associated hepatocellular carcinoma development

scientific article

HBx protein is indispensable for development of viraemia in human hepatocyte chimeric mice.

scientific article published on 10 March 2010

HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy

scientific article published on 10 November 2010

HLA-DQB1*03 confers susceptibility to chronic hepatitis C in Japanese: a genome-wide association study

scientific article

Hepatitis B virus-specific miRNAs and Argonaute2 play a role in the viral life cycle

scientific article

Hepatitis C virus infection suppresses the interferon response in the liver of the human hepatocyte chimeric mouse

scientific article

Hepatocellular carcinoma: towards personalized medicine.

scientific article published on 15 March 2012

Human microRNA hsa-miR-1231 suppresses hepatitis B virus replication by targeting core mRNA.

scientific article published on 16 May 2014

IFNL4 polymorphism effects on outcome of simeprevir, peginterferon, and ribavirin therapy for older patients with genotype 1 chronic hepatitis C.

scientific article

IFNL4/IL-28B haplotype structure and its impact on susceptibility to hepatitis C virus and treatment response in the Japanese population

scientific article published on 19 March 2014

IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy.

scientific article published on 4 February 2011

IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C

scientific article published in July 2011

IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients.

scientific article

Identification of a functional variant in the MICA promoter which regulates MICA expression and increases HCV-related hepatocellular carcinoma risk.

scientific article published on 11 April 2013

Identification of novel HCV deletion mutants in chronic hepatitis C patients

scientific article published on 25 July 2012

Importance of serum concentration of adefovir for Lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B.

scientific article

Improvement of renal dysfunction in a patient with hepatitis C virus-related liver cirrhosis by daclatasvir and asunaprevir combination therapy: A case report.

scientific article

Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation

scientific article published on September 2012

Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state.

scientific article published in September 2011

Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease.

scientific article

Involvement of epithelial cell transforming sequence-2 oncoantigen in lung and esophageal cancer progression.

scientific article published on January 2009

Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice

scientific article published on 10 July 2017

Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C.

scientific article published on 21 December 2013

Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma.

scientific article

Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice

scientific article published on 2 April 2018

Protease Inhibitor Resistance Remains Even After Mutant Strains Become Undetectable by Deep Sequencing

scientific article published on 20 September 2016

Quantitative effect of natural killer-cell licensing on hepatocellular carcinoma recurrence after curative hepatectomy

scientific article published on 18 August 2014

Rapid, Sensitive, and Accurate Evaluation of Drug Resistant Mutant (NS5A-Y93H) Strain Frequency in Genotype 1b HCV by Invader Assay

scientific article

Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients

scientific article published on 11 August 2016

Ribavirin dose reduction during telaprevir/ribavirin/peg-interferon therapy overcomes the effect of the ITPA gene polymorphism.

scientific article published on 16 June 2014

Risk factors for exacerbation of gastroesophageal varices and portosystemic encephalopathy during treatment with nucleos(t)ide analogs for hepatitis B virus-related cirrhosis

scientific article published on 8 November 2017

Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C.

scientific article published on 8 September 2016

Serial profiling of circulating tumor DNA for optimization of anti-VEGF chemotherapy in metastatic colorectal cancer patients

scientific article

Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients.

scientific article

Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy.

scientific article

Serum PAI‐1 is a novel predictor for response to pegylated interferon‐α‐2b plus ribavirin therapy in chronic hepatitis C virus infection ⬇️

scientific article published on September 14, 2011

Severe necroinflammatory reaction caused by natural killer cell-mediated Fas/Fas ligand interaction and dendritic cells in human hepatocyte chimeric mouse.

scientific article published on 10 July 2012

Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma

scientific article published in November 2007

Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: seven cases

scientific article

The association between serum cytokine and chemokine levels and antiviral response by entecavir treatment in chronic hepatitis B patients

scientific article

The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma; comparison with interferon-based therapy

scientific article published on 19 November 2018

The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy.

scientific article published on 10 August 2017

Two patients treated with pegylated interferon/ribavirin/telaprevir triple therapy for recurrent hepatitis C after living donor liver transplantation.

scientific article published on 17 February 2014

Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin.

scientific article

Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology

scientific article published on 28 January 2017

Variation in TP63 is associated with lung adenocarcinoma susceptibility in Japanese and Korean populations

scientific article published on 26 September 2010

Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers

scientific journal article

List of works by Daiki Miki

A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region

A genome-wide association study of chronic hepatitis B identified novel risk locus in a Japanese population

A nonsynonymous polymorphism in semaphorin 3A as a risk factor for human unexplained cardiac arrest with documented ventricular fibrillation

A novel TK-NOG based humanized mouse model for the study of HBV and HCV infections.

A translational study of resistance emergence using sequential direct-acting antiviral agents for hepatitis C using ultra-deep sequencing.

Achievement of sustained viral response after switching treatment from pegylated interferon α-2b to α-2a and ribavirin in patients with recurrence of hepatitis C virus genotype 1 infection after liver transplantation: a case report.

Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection

Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A.

Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy

Circulating microRNA-22 correlates with microRNA-122 and represents viral replication and liver injury in patients with chronic hepatitis B.

Clinicopathological features of elderly patients with hepatitis C virus-related hepatocellular carcinoma

Combination therapies with daclatasvir and asunaprevir on NS3-D168 mutated HCV in human hepatocyte chimeric mice.

Common Variant Near HEY2 Has a Protective Effect on Ventricular Fibrillation Occurrence in Brugada Syndrome by Regulating the Repolarization Current

Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy.

Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients.

Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus

Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study.

Differences in serum microRNA profiles in hepatitis B and C virus infection.

Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones

Effects of bisphosphonate zoledronic acid in hepatocellular carcinoma, depending on mevalonate pathway.

Effects of structural variations of APOBEC3A and APOBEC3B genes in chronic hepatitis B virus infection

Efficacy and safety of daclatasvir plus asunaprevir therapy for chronic hepatitis C patients with renal dysfunction.

Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients.

Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1.

Eradication of hepatitis C virus genotype 1 after liver transplantation by interferon therapy before surgery: Report of three patients with analysis of interleukin-28 polymorphism, hepatitis C virus core region and interferon-sensitivity determining

Erratum to: Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy

Establishment of an infectious genotype 1b hepatitis C virus clone in human hepatocyte chimeric mice

G to A hypermutation of TT virus.

G-to-A hypermutation in hepatitis B virus (HBV) and clinical course of patients with chronic HBV infection

Genetic analyses reveal a role for vitamin D insufficiency in HCV-associated hepatocellular carcinoma development

HBx protein is indispensable for development of viraemia in human hepatocyte chimeric mice.

HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy

HLA-DQB1*03 confers susceptibility to chronic hepatitis C in Japanese: a genome-wide association study

Hepatitis B virus-specific miRNAs and Argonaute2 play a role in the viral life cycle

Hepatitis C virus infection suppresses the interferon response in the liver of the human hepatocyte chimeric mouse

Hepatocellular carcinoma: towards personalized medicine.

Human microRNA hsa-miR-1231 suppresses hepatitis B virus replication by targeting core mRNA.

IFNL4 polymorphism effects on outcome of simeprevir, peginterferon, and ribavirin therapy for older patients with genotype 1 chronic hepatitis C.

IFNL4/IL-28B haplotype structure and its impact on susceptibility to hepatitis C virus and treatment response in the Japanese population

IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy.

IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C

IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients.

Identification of a functional variant in the MICA promoter which regulates MICA expression and increases HCV-related hepatocellular carcinoma risk.

Identification of novel HCV deletion mutants in chronic hepatitis C patients

Importance of serum concentration of adefovir for Lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B.

Improvement of renal dysfunction in a patient with hepatitis C virus-related liver cirrhosis by daclatasvir and asunaprevir combination therapy: A case report.

Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation

Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state.

Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease.

Involvement of epithelial cell transforming sequence-2 oncoantigen in lung and esophageal cancer progression.

Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice

Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C.

Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma.

Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice

Protease Inhibitor Resistance Remains Even After Mutant Strains Become Undetectable by Deep Sequencing

Quantitative effect of natural killer-cell licensing on hepatocellular carcinoma recurrence after curative hepatectomy

Rapid, Sensitive, and Accurate Evaluation of Drug Resistant Mutant (NS5A-Y93H) Strain Frequency in Genotype 1b HCV by Invader Assay

Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients

Ribavirin dose reduction during telaprevir/ribavirin/peg-interferon therapy overcomes the effect of the ITPA gene polymorphism.

Risk factors for exacerbation of gastroesophageal varices and portosystemic encephalopathy during treatment with nucleos(t)ide analogs for hepatitis B virus-related cirrhosis

Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C.

Serial profiling of circulating tumor DNA for optimization of anti-VEGF chemotherapy in metastatic colorectal cancer patients

Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients.

Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy.

Serum PAI‐1 is a novel predictor for response to pegylated interferon‐α‐2b plus ribavirin therapy in chronic hepatitis C virus infection ⬇️

Severe necroinflammatory reaction caused by natural killer cell-mediated Fas/Fas ligand interaction and dendritic cells in human hepatocyte chimeric mouse.

Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma

Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: seven cases

The association between serum cytokine and chemokine levels and antiviral response by entecavir treatment in chronic hepatitis B patients

The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma; comparison with interferon-based therapy

The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy.

Two patients treated with pegylated interferon/ribavirin/telaprevir triple therapy for recurrent hepatitis C after living donor liver transplantation.

Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin.

Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology

Variation in TP63 is associated with lung adenocarcinoma susceptibility in Japanese and Korean populations

Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers